TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06813820: RELIVE (Randomized Evaluation of Less Invasive Ventricular Enhancement) Trial

Sponsor: BioVentrix · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 135 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,759,600

Rescue Site Savings

+$1,162,000

Unlock Full NCT06813820 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06813820 Rescue Dossier →